memantine has been researched along with Optic Nerve Diseases in 11 studies
Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 7.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 3.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Glaucoma is a neurodegenerative disease for which the neuropathic pathology has been studied since 1972." | 2.44 | History of neuroprotection and rationale as a therapy for glaucoma. ( Levin, LA; Peeples, P, 2008) |
| "Pre-treatment with tacrolimus markedly protected RGC-5 cells from NMDA-induced neurotoxicity, and then both spontaneous RGC death and degenerative changes to the optic nerve in p50-deficient mice were significantly reduced by the chronic administration of tacrolimus." | 1.37 | Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. ( Hayashi, T; Murata, T; Nakamura-Yanagidaira, T; Sano, K; Takahashi, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinreb, RN | 3 |
| Liebmann, JM | 1 |
| Cioffi, GA | 1 |
| Goldberg, I | 1 |
| Brandt, JD | 1 |
| Johnson, CA | 1 |
| Zangwill, LM | 1 |
| Schneider, S | 1 |
| Badger, H | 1 |
| Bejanian, M | 1 |
| Danesh-Meyer, HV | 1 |
| Levin, LA | 2 |
| Nakamura-Yanagidaira, T | 1 |
| Takahashi, Y | 1 |
| Sano, K | 1 |
| Murata, T | 1 |
| Hayashi, T | 1 |
| Hare, WA | 2 |
| WoldeMussie, E | 2 |
| Lai, RK | 1 |
| Ton, H | 2 |
| Ruiz, G | 2 |
| Chun, T | 1 |
| Wheeler, L | 2 |
| Wijono, M | 1 |
| Feldmann, B | 1 |
| Zangwill, L | 1 |
| Yücel, YH | 1 |
| Gupta, N | 1 |
| Zhang, Q | 1 |
| Mizisin, AP | 1 |
| Kalichman, MW | 1 |
| Zhong, L | 1 |
| Bradley, J | 1 |
| Schubert, W | 1 |
| Ahmed, E | 1 |
| Adamis, AP | 1 |
| Shima, DT | 1 |
| Robinson, GS | 1 |
| Ng, YS | 1 |
| Kusari, J | 1 |
| Zhou, S | 1 |
| Padillo, E | 1 |
| Clarke, KG | 1 |
| Gil, DW | 1 |
| Peeples, P | 1 |
| Naskar, R | 1 |
| Vorwerk, CK | 1 |
| Dreyer, EB | 1 |
| Pop, E | 1 |
3 reviews available for memantine and Optic Nerve Diseases
| Article | Year |
|---|---|
Neuroprotection: extrapolating from neurologic diseases to the eye.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino | 2009 |
History of neuroprotection and rationale as a therapy for glaucoma.
Topics: Disease Progression; Glaucoma; Humans; Memantine; Neurodegenerative Diseases; Neuroprotective Agents | 2008 |
Saving the nerve from glaucoma: memantine to caspaces.
Topics: Animals; Apoptosis; Caspase Inhibitors; Caspases; Excitatory Amino Acid Antagonists; Glaucoma; Gluta | 1999 |
1 trial available for memantine and Optic Nerve Diseases
| Article | Year |
|---|---|
Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind | 2018 |
7 other studies available for memantine and Optic Nerve Diseases
| Article | Year |
|---|---|
Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Calcineurin; Genes, Reporter; Hum | 2011 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.
Topics: Administration, Oral; Animals; Cell Count; Chronic Disease; Disease Models, Animal; Electroretinogra | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.
Topics: Administration, Oral; Animals; Cell Count; Cell Survival; Disease Models, Animal; Excitatory Amino A | 2004 |
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni | 2006 |
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Topics: Animals; Axons; Cell Survival; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Techniqu | 2007 |
Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood-Retinal Barrier; Body Weight; Cell Count; Coloring Agents; Diabetes Me | 2007 |
Trends in neuroprotection.
Topics: Aged; Amlodipine; Animals; Antiparkinson Agents; Apoptosis; Brain Diseases; Calcium Channel Blockers | 2002 |